Cellectis SA (CLLS)
1.85
-0.01
(-0.54%)
USD |
NASDAQ |
Nov 22, 12:57
Cellectis Profit Margin (Quarterly): -142.3% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -142.3% |
| June 30, 2024 | -313.5% |
| March 31, 2024 | |
| December 31, 2023 | -14.77K% |
| September 30, 2023 | -11.28K% |
| June 30, 2023 | -6.54K% |
| March 31, 2023 | -21.79K% |
| December 31, 2022 | -167.3% |
| September 30, 2022 | -16.17K% |
| June 30, 2022 | -1.45K% |
| March 31, 2022 | -1.92K% |
| December 31, 2021 | |
| September 30, 2021 | -450.2% |
| June 30, 2021 | -357.2% |
| March 31, 2021 | -46.36% |
| December 31, 2020 | |
| September 30, 2020 | -490.3% |
| June 30, 2020 | -1.11K% |
| March 31, 2020 | 40.06% |
| December 31, 2019 | -843.2% |
| Date | Value |
|---|---|
| September 30, 2019 | -188.5% |
| June 30, 2019 | -2.90K% |
| March 31, 2019 | -1.47K% |
| December 31, 2018 | -2.68K% |
| September 30, 2018 | -2.52K% |
| June 30, 2018 | -143.7% |
| March 31, 2018 | -421.2% |
| December 31, 2017 | -469.5% |
| September 30, 2017 | -427.2% |
| June 30, 2017 | -408.1% |
| March 31, 2017 | -293.4% |
| December 31, 2016 | -164.7% |
| September 30, 2016 | -124.8% |
| June 30, 2016 | -39.53% |
| March 31, 2016 | -422.2% |
| December 31, 2015 | 32.43% |
| September 30, 2015 | -168.0% |
| June 30, 2015 | -302.5% |
| March 31, 2015 | 72.92% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-21.79K%
Minimum
Mar 2023
40.06%
Maximum
Mar 2020
-4.58K%
Average
-843.2%
Median
Dec 2019
Profit Margin (Quarterly) Benchmarks
| Edap TMS SA | -48.85% |
| DBV Technologies SA | -- |
| Genfit SA | -- |
| Adaptimmune Therapeutics PLC | -43.07% |
| Akari Therapeutics PLC | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -79.78% |
| Return on Assets | -24.83% |
| Return on Invested Capital | -57.78% |
| Operating Margin (Quarterly) | -66.49% |
| Return on Net Operating Assets | -43.66% |